Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus methotrexate for moderate to severe psoriasis
IRCT20100102002954N26Phase 3Completed
- Sponsor
- Shahroud University of Medical Sciences
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of adalimumab and methotrexate in psoriasis (2 arms), sponsored by Shahroud University of Medical Sciences. Primary endpoints: Psoriasis severity index, Body surface area involved and 1 more. Started Mar 2022; status: completed.
02
Drugs
adalimumabmethotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on IRCT20100102002954N26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100102002954N26.